# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen reiterates LifeMD (NASDAQ:LFMD) with a Buy and maintains $12 price target.
Cantor Fitzgerald analyst Sarah James maintains LifeMD (NASDAQ:LFMD) with a Overweight and raises the price target from $13 ...
LifeMD (NASDAQ:LFMD) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.15) by 106...
LifeMD, Inc.® (NASDAQ:LFMD), a leading provider of virtual primary care services, and Withings Health Solutions, a leader in di...
BTIG analyst David Larsen maintains LifeMD (NASDAQ:LFMD) with a Buy and raises the price target from $13 to $14.